The inventory could possibly be poised for a turnaround.
Billionaire investor Larry Robbins of hedge fund Glenview Capital Administration has taken a big stake in healthcare firm CVS Well being (CVS 2.65%) and has met with administration on methods to assist flip across the struggling enterprise. In line with The Wall Avenue Journal, Glenview has amassed a couple of $700 million stake within the firm.
In the meantime, in line with CNBC, CVS has met with advisors to conduct a strategic overview of its enterprise. The overview began earlier than Glenview grew to become concerned.
The query is: With a billionaire investor taking a big stake in CVS, ought to different traders comply with swimsuit?
CVS’ struggles
CVS has three predominant companies: Healthcare advantages, a retail pharmacy, and a pharmacy profit supervisor (PBM). All the companies have had their share of struggles.
The healthcare advantages enterprise, which incorporates well being insurer Aetna, has struggled due to greater healthcare prices and utilization. Its medical profit ratio (MBR), a measure of claims to premiums earned, elevated by 340 foundation factors final quarter, to 89.6%.
In brief, the upper the quantity, the much less cash the corporate is holding. Healthcare insurance coverage suppliers should pay out 80% of premiums in healthcare prices and high quality enchancment actions, and 85% if they’re promoting to giant teams of fifty or extra staff.
CVS credited the big enhance in its MBR final quarter to greater Medicare Benefit utilization, decrease Stars scores, and elevated Medicaid acuity (sickness severity). The Stars system relies on high quality of care and is used to find out Medicare bonus funds. The upper MBR brought on the section to see a 39% decline in its adjusted working earnings, regardless of a 21% enhance in income and 5% enhance in members.
The corporate additionally up to date its steerage to mirror present medical price developments, which it mentioned could possibly be greater than within the first half. It mentioned if this happens, it could possibly be compelled to take a premium deficiency reserve in its Medicare enterprise, which implies that present fee reserves and future premiums will not be sufficient to pay out unpaid claims and future claims. It now expects its MBR to be 90.6% to 90.8% for the total yr, up 80 foundation factors to 100 foundation factors versus its earlier steerage.
The retail pharmacy enterprise has additionally been below stress from reimbursement charges. This has been an industrywide drawback, as PBMs have relentlessly pushed down reimbursement charges to the purpose the place pharmacies lose cash by filling some subscriptions. CVS does personal the most important PBM in Categorical Scripts, so it has not seen the identical kind of impact as rival Walgreens Boots Alliance.
Nevertheless, the section’s second-quarter adjusted earnings was down 12%, regardless of a 4% enhance in income and 4% enhance in subscriptions being stuffed.
CVS’ PBM section has been the best-performing of its companies. It noticed a slight 1% enhance in adjusted working earnings regardless of dropping a big shopper, which brought on the section’s income to say no by 9% and claims processed to sink by 18%.
Picture supply: Getty Pictures.
Turnaround potential
The corporate may have the chance to repair the Aetna enterprise by higher underwriting when it reprices the enterprise subsequent yr. It seems to have underpriced its insurance policies this yr to win new enterprise, which proved to be an error. CVS mentioned there will likely be important value will increase in 2025 for particular person companies, whereas for Medicaid, value will increase will go into impact on almost half of its e-book at first of the yr. Total, this problem must be fixable over time.
The retail pharmacy and PBM companies, in the meantime, are intertwined in some ways. In any case, it’s PBMs like the corporate’s Categorical Scripts enterprise which are inflicting the reimbursement pressures at pharmacies. There finally will must be a extra sustainable mannequin put in place for pharmacies. But when this does occur, how a lot profit the corporate as a complete will get is unsure, on condition that it owns each a big retail pharmacy and a PBM.
At this level, I feel the corporate prefers the reimbursement stress to the good thing about its PBM and to the detriment of pharmacies, as it’s hurting its rivals extra, and they’re lowering their retailer counts. CVS has already been taking pharmacy share because of this, and it will doubtless solely enhance as Walgreens closes shops.
From a valuation perspective, the inventory is cheap, buying and selling at a ahead price-to-earnings (P/E) of about 8.4 instances primarily based on 2025 analyst estimates. This falls in between a well being insurer like Humana and struggling pharmacy Walgreens.
CVS PE Ratio (Ahead 1y) information by YCharts.
The valuation hole between well being insurers and pharmacies may make it attention-grabbing for the corporate to doubtlessly spin out the Aetna enterprise, the place it ought to be capable to get a better a number of. Regardless, it does seem like there are levers for the corporate to tug to assist flip across the enterprise and create shareholder worth transferring ahead.
I feel traders can comply with Glenview into the identify and be consumers of CVS inventory.
